Drug Interactions and Pharmacokinetics

Fluoroquinolones are notable for high oral bioavailability and wide tissue distribution, but their absorption is markedly reduced by chelation with multivalent metal cations, and several agents historically affected the metabolism of co-administered drugs. Their pharmacokinetics and pharmacodynamics are best understood together, since concentration relative to the pathogen drives both efficacy and resistance suppression.

Definition

Fluoroquinolone pharmacokinetics describes how the drugs are absorbed, distributed, metabolized, and eliminated, while drug interactions describe how co-administered substances (notably multivalent cations and certain CYP substrates) alter fluoroquinolone exposure or the exposure of other drugs.

Scope

The entry covers the absorption, distribution, metabolism, and elimination of fluoroquinolones; the concentration-dependent pharmacodynamics that guide exposure targets; and the principal drug interactions — cation chelation reducing absorption, effects on certain cytochrome P450 substrates such as theophylline, and additive risks such as QT prolongation. It is reference-educational and gives no dosing or individualized advice.

Core questions

• Why do multivalent cations (calcium, magnesium, aluminium, iron, zinc) reduce fluoroquinolone absorption?
• What features make fluoroquinolones suitable for oral and tissue-targeted therapy?
• Which pharmacodynamic indices best describe fluoroquinolone efficacy and resistance suppression?
• Which interactions arise from metabolism (e.g., theophylline) or additive pharmacodynamics (e.g., QT effects)?

Key concepts

• Oral bioavailability and tissue penetration
• Cation chelation (Ca, Mg, Al, Fe, Zn)
• Concentration-dependent killing
• AUC/MIC and Cmax/MIC pharmacodynamic indices
• Mixed renal and hepatic elimination
• Cytochrome P450 interactions (e.g., theophylline)
• Additive QT-interval effects

Mechanisms

Most fluoroquinolones are well absorbed orally and distribute widely into tissues and intracellular compartments, giving large volumes of distribution and supporting use against intracellular and deep-tissue pathogens (Stein, 1996). A key absorption interaction is chelation: the carboxyl and keto groups of the quinolone core bind multivalent metal cations, so co-administration with antacids, mineral supplements, or iron salts forms poorly absorbed complexes and substantially lowers bioavailability (Owens & Ambrose, 2005). Elimination varies by agent between renal and hepatic routes. Pharmacodynamically, fluoroquinolones kill in a concentration-dependent manner, so exposure indices such as the ratio of area under the concentration-time curve to the minimum inhibitory concentration (AUC/MIC) and peak concentration to MIC (Cmax/MIC) describe both efficacy and the suppression of resistant subpopulations (Wispelwey, 2005). Some agents historically inhibited cytochrome P450 enzymes and raised concentrations of substrates such as theophylline, and several share additive potential for QT-interval prolongation with other QT-affecting drugs (Owens & Ambrose, 2005).

Clinical relevance

The cation-chelation interaction and the concentration-dependent pharmacodynamics are central to understanding how fluoroquinolone exposure is achieved and why certain co-medications matter, which is why they feature in pharmacology teaching and evidence appraisal. This entry explains these principles for educational purposes and does not provide dosing, timing, or individualized management advice.

Evidence & guidelines

The pharmacokinetic-pharmacodynamic framework and exposure targets are drawn from class PK-PD reviews (Wispelwey, 2005; Stein, 1996), and the interaction and safety considerations from class-safety reviews (Owens & Ambrose, 2005). These are mechanistic and PK-PD references rather than dosing guidelines; current product labelling and guidelines should be consulted directly for specific recommendations.

History

As fluoroquinolones entered wide oral use in the 1980s and 1990s, the cation-chelation interaction and metabolism-based interactions (notably with theophylline) were characterized, and PK-PD analysis established AUC/MIC and Cmax/MIC as the indices linking exposure to outcome and resistance suppression — a framework that influenced later development and dosing strategy across the class.

Key figures

• Brian Wispelwey
• Gary E. Stein
• Robert C. Owens

Seminal works

• wispelwey-2005
• stein-1996

Frequently asked questions

Why can antacids or mineral supplements reduce fluoroquinolone effectiveness?

Fluoroquinolones chelate multivalent metal cations such as calcium, magnesium, aluminium, iron, and zinc; taken together they form poorly absorbed complexes, substantially lowering the amount of antibiotic absorbed. This is a well-recognized absorption interaction.

What pharmacodynamic measures describe fluoroquinolone activity?

Because killing is concentration-dependent, exposure indices such as AUC/MIC and Cmax/MIC are used to relate drug exposure to efficacy and to the suppression of resistant subpopulations.